OPDIVO (Nivolumab) Drug Pipeline Research Report 2024: The First-in-human Immunoglobulin G4 (IgG4) PD-1 Immune Checkpoint Inhibitor Antibody - Market Size, Forecast, and Emerging Insights 2019-2032 - ResearchAndMarkets.com
This report provides comprehensive insights about OPDIVO for ovarian cancer in the six major markets.
- This report provides comprehensive insights about OPDIVO for ovarian cancer in the six major markets.
- The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
- OPDIVO (also known as Nivolumab) is the first-in-human immunoglobulin G4 (IgG4) PD-1 immune checkpoint inhibitor antibody that disrupts the interaction of the PD-1 receptor with its ligands PD-L1 and PD-L2, thereby inhibiting the cellular immune response.
- What are the other emerging products available and how are these giving competition to OPDIVO for ovarian cancer?